Surgical treatment of resectable and borderline resectable pancreatic cancer: Expert consensus statement by Evans et al.

Annals of Surgical Oncology

Volumn 16, Issue 7, 2009, Pages 1745-1750

  Adams, Reid B ^a   Allen, Peter J ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PALLIATIVE THERAPY; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; CONFERENCE PAPER; HUMAN; LYMPH NODE DISSECTION; LYMPHADENECTOMY; OUTCOME ASSESSMENT; PANCREAS CANCER; PANCREATICODUODENECTOMY; PROGNOSIS; SURGICAL TECHNIQUE; TREATMENT INDICATION; TREATMENT OUTCOME;

ADENOCARCINOMA; HUMANS; LYMPH NODE EXCISION; NEOPLASM STAGING; PALLIATIVE CARE; PANCREAS; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROGNOSIS; VASCULAR NEOPLASMS; VASCULAR SURGICAL PROCEDURES;

EID: 67649229696     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0410-z     Document Type: Conference Paper

References (29)

1. Fortner JG. Regional resection and pancreatic carcinoma. Surgery. 1973;73:799-800.
2. Pawlik TM, Abdalla EK, Barnett CC, et al. Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer. Arch Surg. 2005;140:584-9.
3. Greene F, Page D, Fleming I, et al. AJCC cancer staging manual. New York: Springer, 2002.
4. Tomlinson JS, Jain S, Bentrem DJ, et al. Accuracy of staging node-negative pancreas cancer: a potential quality measure. Arch Surg. 2007;142:767-23.
5. Wong SL, Ji H, Hollenbeck BK, et al. Hospital lymph node examination rates and survival after resection for colon cancer. JAMA. 2007;298:2149-54.
6. Simunovic M, Baxter NN. Lymph node counts in colon cancer surgery: lessons for users of quality indicators. JAMA. 2007;298: 2194-5.
7. Tseng JF, Raut CP, Lee JE, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg. 2004;8:935-49.
8. Riediger H, Makowiec F, Fischer E, et al. Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection. J Gastrointest Surg. 2006;10:1106-15.
9. Birkmeyer JD, Sun Y, Wong SL, Stukel TA. Hospital volume and late survival after cancer surgery. Ann Surg. 2007;245:777-83.
10. Chappel AR, Zuckerman RS, Finlayson SR. Small rural hospitals and high-risk operations: how would regionalization affect surgical volume and hospital revenue? J Am Coll Surg. 2006;203: 599-604.
11. Halm EA, Lee C, Chassin MR. Is volume related to outcome in health care? A systematic review and methodologic critique of the literature. Ann Intern Med. 2002;137:511-20.
12. Loyer EM, David CL, Dubrow RA, et al. Vascular involvement in pancreatic adenocarcinoma: reassessment by thin-section CT. Abdom Imaging. 1996;21:202-6.
13. Lu DS, Reber HA, Krasny RM, et al. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol. 1997;168:1439-43.
14. O'Malley ME, Boland GW, Wood BJ, et al. Adenocarcinoma of the head of the pancreas: determination of surgical unresectability with thin-section pancreatic-phase helical CT. AJR Am J Roentgenol. 1999;173:1513-8.
15. Phoa SS, Reeders JW, Stoker J, et al. CT criteria for venous invasion in patients with pancreatic head carcinoma. Br J Radiol. 2000;73(875):1159-64.
16. Diehl SJ, Lehmann KJ, Sadick M, et al. Pancreatic cancer: value of dual-phase helical CT in assessing resectability. Radiology. 1998;206:373-8.
17. Bilimoria KY, Bentrem DJ, Ko CY, et al. Multimodality therapy for pancreatic cancer in the U.S.: utilization, outcomes, and the effect of hospital volume. Cancer. 2007;110:1227-34.
18. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567-79.
19. Wagner M, Redaelli C, Lietz M, et al. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004;91:586-94.
20. Raut CP, Tseng JF, Sun CC, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg. 2007;246:52-60.
21. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-10.
22. Butturini G, Stocken DD, Wente MN, et al. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg. 2008;143:75-83.
23. Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13:1035-46.
24. Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008;206:833-46.
25. Pingpank JF, Hoffman JP, Ross EA, et al. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg. 2001; 5:121-30.
26. Howard TJ, Krug JE, Yu J, et al. A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon's contribution to long-term survival in pancreatic cancer. J Gastrointest Surg. 2006;10:1338-45.
27. Tseng JF, Pisters PW, Lee JE, et al. The learning curve in pancreatic surgery. Surgery. 2007;141:694-701.
28. Miner TJ, Jaques DP, Karpeh MS, Brennan MF. Defining palliative surgery in patients receiving noncurative resections for gastric cancer. J Am Coll Surg. 2004;198:1013-21.
29. McCahill LE, Krouse RS, Chu DZ, et al. Decision making in palliative surgery. J Am Coll Surg. 2002;195:411-22.